Deliver Your News to the World

Frost & Sullivan Acknowledges CytoGenix’s Revolutionary Approach to Large-scale Production of Clinical-grade DNA


Palo Alto, Calif. — June 28, 2006 — Frost & Sullivan has selected CytoGenix, Inc. as the recipient of the 2006 Frost & Sullivan Award for Technology Innovation in biotechnology processing for introducing a fundamental improvement to the large-scale production of DNA. This technology is especially useful in the rapid production of DNA vaccines for pandemic and bioterror applications.

CytoGenix has developed a cell-free production process that enables generation of large quantities of high-purity DNA in small, highly automated production modules at a fraction of the time and cost of traditional bioprocess methods. This breakthrough technology can enhance drug development, and in turn, help protect the lives of millions of people from pandemic disease.

CytoGenix’ method is likely to be safer than standard methods (for example, there is a lower risk of allergy). In addition, it takes less than three months to produce a market-ready vaccine from start to finish. The final product does not require refrigeration as standard vaccines do, and this could make a significant difference in vaccination rates in countries where electricity is often not available.

From a regulatory and compliance perspective, the benefits provided by cell-free synthesis are significant and similar to processes for small-molecule drug production.

The CytoGenix technology does not require methods for cell collection, processing, and culture maintenance, which will significantly reduce quality-assurance, quality control, and compliance overhead costs compared to traditional methods. The entire process is bench-scale and requires less equipment, less space and less human intervention compared to bioprocess manufacturing facilities.

“Moreover, the total absence of bacteria and growth media means that there is no need to employ mechanical or chemical purification methods to extract cell or animal proteins, RNA, genomic DNA, and backbone molecules,” says Frost & Sullivan Research Analyst Katherine Austin. “This feature provides the designer more control over coding for non-specific and specific immune responses.”

CytoGenix has completed the design and construction of a prototype production module for high-quality, cell-free DNA. The company is now implementing standard operating procedures to comply with current good manufacturing practice (cGMP) to enable the production of clinical-grade material.

“As the list of therapeutic antisense molecules continues to grow and more disease states are targeted, the need for dependable delivery and expression systems will increase accordingly,” notes Austin. “The CytoGenix technology will speed development and production of these as well.”

Each year Frost & Sullivan presents this Award to a company that has carried out new research that has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This Award recognizes the quality and depth of a company’s research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About CytoGenix, Inc.

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 47 international or US pending patent applications claiming methods and materials in connection with this platform technology.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit or


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.